Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

This study has been completed.

Study NCT00079274 Information provided by National Cancer Institute (NCI)

First Received: March 8, 2004 Last Updated: November 15, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	November 2011 (Final data collection date for primary outcome measure)

Publications:

Alberts, SR, Sargent DJ, Smyrk TC, et al.: Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147. [Abstract] J Clin Oncol 28 (Suppl 18): A-CRA3507, 2010.

Goldberg RM, Sargent DJ, Thibodeau SN, et al.: Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. [Abstract] J Clin Oncol 28 (Suppl 15): A-3508, 2010.

Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR. Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147. Oncology. 2009 Jul 22;77(2):120-123 [Epub ahead of print]